The efficacy of inactivated West Nile vaccine (WN-VAX) in mice and monkeys

Virology Journal

Volumn 12, Issue 1, 2015, Pages

  Muraki, Yuko ^a   Fujita, Takeshi ^a   Matsuura, Masaaki ^a   Fuke, Isao ^a   Manabe, Sadao ^a   Ishikawa, Toyokazu ^a   Okuno, Yoshinobu ^a   Morita, Kouichi ^b  

^a The Research Foundation for Microbial Diseases of Osaka University   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

Author keywords

Challenge test in mouse; Efficacy in monkey; Formalin inactivated vaccine; West Nile Virus

Indexed keywords

NEUTRALIZING ANTIBODY; WEST NILE VACCINE; INACTIVATED VACCINE; VIRUS ANTIBODY;

ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; IMMUNOGENICITY; INFECTION PREVENTION; MACACA FASCICULARIS; NONHUMAN; PASSIVE IMMUNIZATION; PROVOCATION TEST; VACCINATION; WEST NILE FEVER; ANIMAL; BLOOD; DISEASE MODEL; HAPLORHINI; IMMUNIZATION; IMMUNOLOGY; MORTALITY; MOUSE; SERODIAGNOSIS; WEST NILE VIRUS;

AVES; EQUIDAE; FLAVIVIRIDAE; FLAVIVIRUS; MACACA FASCICULARIS; MUS; PRIMATES; WEST NILE VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; HAPLORHINI; IMMUNIZATION; MICE; NEUTRALIZATION TESTS; VACCINES, INACTIVATED; WEST NILE FEVER; WEST NILE VIRUS; WEST NILE VIRUS VACCINES;

EID: 84928010772     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/s12985-015-0282-8     Document Type: Article

References (16)

1. Nash D, Mostashari F, Fine A, Miller J, O'Leary D, Murray K, et al. The outbreak of West Nile virus infection in the New York City area in 1999. N Engl J Med. 2001;344(24):1807-14.
2. West Nile virus activity - United States, 2009. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010; 59(25):769-72. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5925a1.htm. Accessed on April 15.
3. Chowdhury P, Ahmed Khan S, Topno R, Dutta P, Yadav RN, Mahanta J. Immunogenic potential and protective efficacy of formalin inactivated circulating Indian strain of West Nile virus. Asian Pac J Trop Med. 2014;7(12):946-51.
4. Ledgerwood JE, Pierson TC, Hubka SA, Desai N, Rucker S, Gordon IJ, et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J Infect Dis. 2011;203(10):1396-404.
5. Biedenbender R, Bevilacqua J, Gregg AM, Watson M, Dayan G. Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults. J Infect Dis. 2011;203(1):75-84.
6. Arroyo J, Miller C, Catalan J, Myers GA, Ratterree MS, Trent DW, et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol. 2004;78(22):12497-507.
7. Kikukawa A, Gomi Y, Akechi M, Onishi T, Manabe S, Namazue J, et al. Superior immunogenicity of a freeze-dried, cell culture-derived Japanese encephalitis vaccine (inactivated). Vaccine. 2012;30(13):2329-35.
8. Posadas-Herrera G, Inoue S, Fuke I, Muraki Y, Mapua CA, Khan AH, et al. Development and evaluation of a formalin-inactivated West Nile Virus vaccine (WN-VAX) for a human vaccine candidate. Vaccine. 2010;28(50):7939-46.
9. Expert committee on biological standardization Geneva - 8 to 12 October 2007 proposed revision recommendations for Japanese encephalitis vaccine (inactivated) for human use. http://www.who.int/biologicals/publications/trs/areas/vaccines/jap-encephalitis/Japanese%20Encephatis%20guidelines%202007%20revised%20211207%20rev07.pdf?ua=1. Accessed on April 15.
10. Ferguson M, Kurane I, Wimalaratne O, Shin J, Wood D, WHO informal consultation group. WHO informal consultation on the scientific basis of specifications for production and control of inactivated Japanese encephalitis vaccines for human use, Geneva, Switzerland, 1-2 June 2006. Vaccine. 2007;25(29):5233-43.
11. Tesh RB, Arroyo J, Travassos Da Rosa AP, Guzman H, Xiao SY, Monath TP. Efficacy of killed virus vaccine, live attenuated chimeric virus vaccine, and passive immunization for prevention of West Nile virus encephalitis in hamster model. Emerg Infect Dis. 2002;8(12):1392-7.
12. Oya A. Japanese encephalitis vaccine. Acta Paediatr Jpn. 1988;30(2):175-84.
13. Hamdan A, Green P, Mendelson E, Kramer MR, Pitlik S, Weinberger M. Possible benefit of intravenous immunoglobulin therapy in a lung transplant recipient with West Nile virus encephalitis. Transpl Infect Dis. 2002;4(3):160-2.
14. Makhoul B, Braun E, Herskovitz M, Ramadan R, Hadad S, Norberto K. Hyperimmune gammaglobulin for the treatment of West Nile virus encephalitis. Isr Med Assoc J. 2009;11(3):151-3.
15. Walid MS, Mahmoud FA. Successful treatment with intravenous immunoglobulin of acute flaccid paralysis caused by west nile virus. Perm J. 2009;13(3):43-6.
16. Hombach J, Solomon T, Kurane I, Jacobson J, Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine. 2005;23(45):5205-11.